P19 Incidence and implications of pseudoprogression in women with advanced or recurrent endometrial cancer on pembrolizumab/lenvatinib combination therapy
To describe our experience with pseudoprogression in women with advanced/recurrent endometrial cancer on pembrolizumab/lenvatinib, including latency and duration of response.
PDF的下载单位、IP信息已删除
(2025-6-4)
科研通AI6.2
Adc
聪慧鸭子
Cakoibao
互助
沈清酌
eric888
GingerF
小翼
yznfly
tuanheqi
loii
无情采文
王叮叮
123
淡然冬灵
云天
猫咪毛毛
好为
專注完美近乎苛求
小蘑菇
田様
慕青
酷波er
皖公网安备34019202002308
